ASX Announcement

30 January 2026

Quarterly Activities Report
for the period ending 31 December 2025

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 31 December 2025 (Q2 FY2026), together with its Appendix 4C Quarterly Cash Flow Report.

HIGHLIGHTS

- US Food and Drug Administration (FDA) grants Rare Pediatric Disease Designation (RPDD) for lead drug candidate, NTI164, for the treatment of Rett syndrome
- Clinical and mechanistic data for proprietary drug NTI164 published in leading scientific journal
- Balance sheet strengthened following $4m Placement and $4.73m R&D tax incentive refund

R&D UPDATES

US FDA Rare Pediatric Disease Designation for NTI164 in Rett syndrome

In October, the US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation (RPDD) for Neurotech's lead drug candidate NTI164 in Rett syndrome.

This designation builds on the Orphan Drug Designations already in place for NTI164 in Rett syndrome in the United States and Europe and further strengthens Neurotech's regulatory position in the development of therapies for rare paediatric neurological disorders.

The RPDD program applies to serious or life-threatening diseases affecting fewer than 200,000 people in the United States. In granting the designation, the FDA confirmed that Rett syndrome meets the statutory definition of a "rare disease or condition" per section 526 of the FD&C Act.

When combined with Orphan Drug Designation, RPDD provides access to enhanced FDA support during development, potential priority review, tax credits for clinical testing, exemptions from certain FDA fees, and if approved, seven years of market exclusivity in the United States, materially strengthening the commercial and partnering profile of NTI164.

NTI164 is Neurotech's broad-spectrum oral cannabinoid drug therapy which is being evaluated across multiple neurodevelopmental disorders including autism spectrum disorder, Rett syndrome, and PANDAS/PANS.

PANS Clinical & Mechanistic Data Published in Leading Scientific Journal

Subsequent to the end of the quarter, Neurotech announced the publication of clinical and mechanistic data for its lead drug NTI164 in *Neurotherapeutics*, a leading peer-reviewed journal and the official journal of the American Society for Experimental NeuroTherapeutics. The publication reports results from a sub-cohort of patients enrolled in Neurotech's Phase I/II open-label clinical trial in Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), alongside a comprehensive multi-omics analysis examining immune and epigenetic pathways.

The study evaluated NTI164 administered orally at 20 mg/kg/day over 12 weeks in 14 children with chronic, relapsing PANS, a severe neuroimmune disorder with no approved treatments. NTI164 was well tolerated, with no serious adverse events and only mild, self-limiting side effects reported.

Clinically, treatment led to statistically significant improvements across all major disease domains, including overall disease severity, anxiety, obsessive-compulsive symptoms, tics, ADHD symptoms and quality of life.

Importantly, the mechanistic analysis demonstrated that children with PANS exhibit widespread dysregulation of epigenetic, ribosomal and immune pathways, and that these same pathways were significantly normalised following NTI164 treatment. This included restoration of ribosomal and mitochondrial function and broad modulation of immune and inflammatory signalling, providing molecular evidence that supports the observed clinical improvements.

Publication of this data in a high-impact scientific journal further strengthens the scientific foundation of NTI164 and provides independent validation of its therapeutic potential across PANS and other neuroinflammatory paediatric indications, supporting Neurotech's broader clinical development strategy.

CORPORATE ACTIVITIES

Binding Commitments Received for ~$4M Placement

Neurotech strengthened its balance sheet during the quarter after receiving binding commitments for a ~$4 million Placement from a mix of existing and new institutional, professional and sophisticated investors.

Funds raised are being directed toward advancing NTI164 through non-clinical toxicology and registration-enabling clinical programs, alongside ongoing regulatory activities and general working capital. These activities are designed to support the transition of NTI164 toward later-stage clinical development and to underpin future regulatory engagement in key jurisdictions.

The Placement was also notable for the participation of the Company's Board, with all directors electing to invest, subject to shareholder approval. This alignment reflects management and Board confidence in the Company's strategy, the clinical profile of NTI164, and the opportunity to build a differentiated paediatric neurology platform around this asset.

Neurotech enters 2026 with a strengthened financial position and the capacity to maintain development momentum across its paediatric neurological disorder programs. The capital raise supports the Company's broader strategy of building regulatory and commercial optionality around NTI164 as it moves toward later-stage trials and progresses potential partnering discussions.

$4.73m R&D Tax Incentive Refund

During the quarter, the Company received a research and development (R&D) tax incentive refund for the financial year ended 30 June 2025 for a total of $4.73 Million. The refund is received as part of the Australian Government's R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%.

Appendix 4C Commentary

During the quarter, the Company recorded total cash operating expenses (excluding revenue sources) of ~$3.4 million (Q1 FY2026: $1.2 million), consisting of research and development costs of ~$3.1 million (Q1 FY2026: $0.8 million), along with advertising, marketing, staff, administrative, and corporate costs of ~$0.3 million (Q1 FY2026: $0.4 million). R&D expenditure during the quarter primarily reflected continued investment in IND-enabling pre-clinical development and toxicology activities to support both FDA IND and TGA applications. Additional R&D spend related to ongoing extension phase activities for the Phase II/III ASD clinical trial, including site operations, patient monitoring, data

management, and clinical oversight costs. Further expenditure was incurred in relation to the Phase I/II clinical trials in Rett Syndrome, comprising trial conduct, safety monitoring, and associated clinical operations. R&D expenditure also included ongoing maintenance and follow-up costs for participants transitioning into extension phases of previous clinical trials, together with drug product manufacturing and development activities, quality and stability programs, and regulatory development work supporting current and planned regulatory submissions.

Total operating cash inflows for the quarter were ~$1.2 million (Q1 FY2026: cash outflows of $1.2 million) driven by the $4.73 Million R&D tax incentive rebate received during the quarter.

The Company closed the quarter with cash and cash equivalents of ~$6.3 million (Q1 FY26: $1.7 million).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C totalled $166,000.

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Neurotech International Limited	
ABN	**Quarter ended ("current quarter")**
73 610 205 402	31 December 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	0	0
1.2	Payments for		
	(a) research and development	(3,195)	(4,014)
	(b) product manufacturing and operating costs	0	0
	(c) advertising and marketing	(39)	(115)
	(d) leased assets	0	0
	(e) staff costs	(118)	(196)
	(f) administration and corporate costs	(126)	(413)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	3	7
1.5	Interest and other costs of finance paid	(2)	(3)
1.6	Income taxes paid	0	0
1.7	Government grants and tax incentives (R&D Rebate)	4,734	4,734
1.8	Other (GST refunds)	0	0
1.9	**Net cash from / (used in) operating activities**	**1,257**	**0**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,454	3,454
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(146)	(146)
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	**Net cash from / (used in) financing activities**	**3,308**	**3,308**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,775	3,032
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,257	0
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,308	3,308
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	**Cash and cash equivalents at end of period**	**6,340**	**6,340**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	6,325	1,760
5.2	Call deposits	15	15
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,340**	**1,775**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	166
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Payments at section 6. relate to director fees ($61,000), executive salaries and reimbursement ($105,000).

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	65	0
7.2	Credit standby arrangements	0	0
7.3	Other (please specify)	0	0
7.4	**Total financing facilities**	65	0

7.5	**Unused financing facilities available at quarter end**	65

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Overdraft facility with a limit of EUR 40,000. The lender is Bank of Valetta. The facility is unsecured. The interest rate is 5.65%.

The above values are stated in AUD, converted from EUR at an exchange rate of 0.564.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	1,257
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,340
8.3	Unused finance facilities available at quarter end (item 7.5)	65
8.4	Total available funding (item 8.2 + item 8.3)	6,405
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	5.10

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 January 2026
.....

Authorised by: The Board of Directors
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.